title: The effects of thiazolidinedione treatment on the regulations of aquaglyceroporins and glycerol kinase in OLETF rats.
abstract: Aquaporins (AQPs) that transport glycerol in addition to water are classified as aquaglyceroporins (AQP3, 7, 9). AQP7 in the adipose tissue and AQP9 in the liver may coordinately contribute to the increase in hepatic gluconeogenesis in states of insulin resistance. Thiazolidinedione (TZD) has been shown to increase adipose AQP7 and induce glycerol kinase (GlyK) which is nearly absent in adipocytes. In the present study, we analyzed both GlyK and AQP gene expression in adipose and hepatic tissues, and AQP3 in kidneys from Long-Evans Tokushima Otsuka (LETO), Otsuka Long-Evans Tokushima Fatty (OLETF), and rosiglitazone (RSG)-treated OLETF (RSG-OLETF) rats. We also evaluated AQP9 protein expression in cultured human hepatoma cells treated with oleic acid, Wy14643, or RSG. A 2-week RSG treatment increased AQP7 mRNA levels in the mesenteric fat, but not in the epididymal fat of OLETF rats. Rosiglitazone treatment markedly increased GlyK expression in both fat depots, with a greater increase in the mesenteric fat. The magnitudes of GlyK induction by RSG were greater than that of AQP7 in both adipose tissues (P < .05, each). AQP9 and GlyK levels in the liver were not affected by RSG treatment in OLETF rats. Oleic acid and Wy14643 upregulated AQP9 protein expression in cultured human hepatoma cells in a dose-dependent manner. AQP3 mRNA levels tended to increase in the outer medulla of the RSG-OLETF rats. These results indicate that in the adipose tissue TZD has an important role in the glycerol metabolic pathway through the regulation of AQP and GlyK, especially by GlyK induction. Free fatty acids may directly enhance glycerol availability in the liver via the upregulation of AQP9 levels. Renal AQP3 may be related to the fluid retention caused by TZD.
authors.affiliation: Department of Medicine, College of Medicine, Cheju National University, Jeju 690-756, Republic of Korea.
authors.forename: Dae-Ho
authors.initials: DH
authors.lastname: Lee
authors.forename: Deok-Bae
authors.initials: DB
authors.lastname: Park
authors.forename: Young-Ki
authors.initials: YK
authors.lastname: Lee
authors.forename: Chun-San
authors.initials: CS
authors.lastname: An
authors.forename: You-Sung
authors.initials: YS
authors.lastname: Oh
authors.forename: Jung-Sook
authors.initials: JS
authors.lastname: Kang
authors.forename: Sin-Hae
authors.initials: SH
authors.lastname: Kang
authors.forename: Min-Young
authors.initials: MY
authors.lastname: Chung
mesh_terms: D000273:Adipose Tissue / Q000378:metabolism; D000818:Animals; D051400:Aquaporin 3; D020346:Aquaporins / Q000235:genetics*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005786:Gene Expression Regulation / Q000187:drug effects*; D005991:Glycerol Kinase / Q000235:genetics*; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D020318:Rats, Long-Evans; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*
chemical_list: C496029:Aqp3 protein, rat; C491926:Aqp7 protein, rat; C491637:Aqp9 protein, rat; D020346:Aquaporins; D005230:Fatty Acids, Nonesterified; D007004:Hypoglycemic Agents; D012333:RNA, Messenger; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D051400:Aquaporin 3; D005991:Glycerol Kinase